Pudong issues the first ABSL-2 certificate, and biopharmaceutical companies and hospitals "hold hands"
On August 29th, the "First Pudong New Area Clinical Research and Application Alliance Summit Forum" was held at Dongfang Hospital. Baiyun, the director of the Pudong New Area Health Commission, awarded Shanghai Pengli Biotechnology Pharmaceutical Research Co., Ltd. the first ABSL-2 certificate in the new area. At the meeting, it was also announced that the Clinical Trial Quality Control Group was established in Pudong New Area, marking the further acceleration of the formation of a higher quality clinical research and development ecosystem for the development of biopharmaceuticals in Pudong New Area.
Clinical research, achievement transformation, and clinical application, as the three major links of medical industry integration, cannot be separated from the precise and efficient connection between medical institutions, research institutions, and biopharmaceutical enterprises in terms of resources, information, and projects. In June of this year, the Clinical Research and Application Alliance in Pudong New Area was established, led by the New Area Health Commission, in conjunction with the Science and Technology Commission and the Market Supervision Bureau. At the same time, the "Pudong New Area Medical Industry Integration Innovation Strategy Source Platform" has been launched. The alliance plays a role as a bridge and link, building a platform for the integration and development of healthcare and industry, promoting business docking such as clinical research, achievement transformation, and product promotion, and achieving functions such as policy promotion, work promotion, information exchange, resource sharing, and academic exchange.
The General Office of the Municipal Government has issued several opinions on promoting the high-quality development of the biopharmaceutical industry in this city, which clearly proposes to build an innovative highland with international influence in the biopharmaceutical industry and make every effort to build a world-class biopharmaceutical industry cluster. The Pudong New Area carries the world's leading biopharmaceutical industry cluster. The tertiary hospitals located in Pudong are unique and should actively cooperate with enterprises, participate in clinical research before going public, increase clinical applications after going public, and be at the forefront of technological innovation. Taking the Tumai surgical robot of a minimally invasive company as an example, hospitals such as Renji and Gongli actively participated in robot research and development, which led to the rapid launch of this robot and became the most powerful catcher of the world's most advanced surgical robots.
As the only district level tertiary comprehensive hospital in Pudong New Area, Dongfang Hospital adheres to the concept of "clinical first, talent first, and discipline first". In recent years, it has continuously made refreshing progress in scientific and technological innovation, including Li Qiang's team's pioneering "bronchial tube cryosurgery for nerve removal" to treat refractory asthma, Professor Chen Yihan, Zhang Qi, and Liu Jun's team's world first complex heart surgery in the same stage for both internal and external cardiology, and Xu Meidong's team's independent research and development of "self-control anti stenosis water bag" to prevent benign esophageal stenosis.
Academician of the Chinese Academy of Sciences, Vice President of Tongji University, and Dean of Dongfang Hospital, Chen Yihan, stated that the high-quality development of tertiary hospitals includes two standards: first, clinical medical capabilities, which should be able to treat difficult and critically ill patients; The second is clinical research on medical technology innovation. This summit forum is the first grand event since the establishment of the Pudong Clinical Research and Application Alliance. On the basis of good cooperation with existing medical enterprises, Dongfang Hospital will further strengthen the integration of medical and industry, efficiently connect with biopharmaceutical enterprises in terms of resources, information, projects, etc., accelerate clinical research and transformation, promote the priority and rapid admission of innovative pharmaceutical products, and enable more research results to be transformed to better serve patients.
![Pudong issues the first ABSL-2 certificate, and biopharmaceutical companies and hospitals "hold hands"](https://a5qu.com/upload/images/9a399441a066dc354fe2874f53bd668a.jpg)
It is reported that the first batch of member units of the alliance include relevant committees and bureaus such as the District Health Commission, Science and Technology Commission, and Market Supervision Bureau, as well as Shanghai University of Technology and some municipal and district level second and third hospitals, as well as the first batch of innovative pharmaceutical product related enterprises in Pudong New Area.
At this forum, Tongji University Affiliated Oriental Hospital signed strategic cooperation agreements with a group of enterprises, including three biopharmaceutical companies: Mengke Pharmaceutical, Hengrui Pharmaceutical, and Zaiding Pharmaceutical, as well as three clinical research service companies: ClinChoice Kunling, Kangde Hongyi, and Yaoming Jinshi.
Text: Zhang Qi
Photography: Min Di
*Reprinted from official WeChat account released by Pudong
![Pudong issues the first ABSL-2 certificate, and biopharmaceutical companies and hospitals "hold hands"](https://a5qu.com/upload/images/7b9c3a84a31da46fc13625e1b45872a1.jpg)